S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)

Humana (HUM) Price Target & Analyst Ratings

$509.83
+5.14 (+1.02%)
(As of 04:33 PM ET)
Compare
Today's Range
$501.33
$510.12
50-Day Range
$485.46
$535.96
52-Week Range
$418.70
$571.30
Volume
551,612 shs
Average Volume
975,718 shs
Market Capitalization
$63.70 billion
P/E Ratio
20.71
Dividend Yield
0.69%
Price Target
$599.72

Humana Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 15 Analyst Ratings

Consensus Analyst Price Target

$599.72
17.63% Upside
High Prediction$652.00
Average Prediction$599.72
Low Prediction$510.00
TypeCurrent
6/8/22 to 6/8/23
1 Month Ago
5/9/22 to 5/9/23
3 Months Ago
3/10/22 to 3/10/23
1 Year Ago
6/8/21 to 6/8/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
15 Buy rating(s)
14 Buy rating(s)
12 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$599.72$597.37$594.12$494.56
Predicted Upside17.63% Upside18.07% Upside17.52% Upside14.56% Upside
Get Humana Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.


HUM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Humana Stock vs. The Competition

TypeHumanaMedical CompaniesS&P 500
Consensus Rating Score
2.93
2.66
2.49
Consensus RatingModerate BuyBuyHold
Predicted Upside18.83% Upside1,239.58% Upside228.69% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/30/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$625.00 ➝ $576.00+15.99%
4/27/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$562.00 ➝ $568.00+12.37%
4/27/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$640.00 ➝ $600.00+18.70%
4/20/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$597.00+21.76%
4/13/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold$560.00 ➝ $590.00+10.89%
4/11/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$620.00 ➝ $637.00+21.44%
2/6/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$647.00 ➝ $581.00+21.91%
2/6/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$635.00 ➝ $575.00+20.65%
2/3/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$625.00 ➝ $590.00+20.41%
2/2/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$645.00 ➝ $620.00+20.79%
12/13/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$575.00 ➝ $652.00+23.02%
11/10/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$529.00 ➝ $615.00+10.74%
11/8/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$558.00 ➝ $610.00+9.92%
11/7/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$547.00 ➝ $647.00+17.20%
11/3/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$540.00 ➝ $640.00+14.37%
11/3/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$560.00 ➝ $637.00+13.84%
9/16/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$520.00 ➝ $550.00+10.61%
6/16/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$510.00+20.47%
(Data available from 6/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












HUM Price Target - Frequently Asked Questions

What is Humana's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Humana stock is Moderate Buy based on the current 1 hold rating and 14 buy ratings for HUM. The average twelve-month price prediction for Humana is $599.72 with a high price target of $652.00 and a low price target of $510.00. Learn more on HUM's analyst rating history.

Do Wall Street analysts like Humana more than its competitors?

Analysts like Humana more than other Medical companies. The consensus rating for Humana is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how HUM compares to other companies.

Does Humana's stock price have much upside?

According to analysts, Humana's stock has a predicted upside of 17.30% based on their 12-month price targets.

What analysts cover Humana?

Stock Ratings Reports and Tools

This page (NYSE:HUM) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -